Literature DB >> 27323698

Measuring the individual benefit of a medical or behavioral treatment using generalized linear mixed-effects models.

Francisco J Diaz1.   

Abstract

We propose statistical definitions of the individual benefit of a medical or behavioral treatment and of the severity of a chronic illness. These definitions are used to develop a graphical method that can be used by statisticians and clinicians in the data analysis of clinical trials from the perspective of personalized medicine. The method focuses on assessing and comparing individual effects of treatments rather than average effects and can be used with continuous and discrete responses, including dichotomous and count responses. The method is based on new developments in generalized linear mixed-effects models, which are introduced in this article. To illustrate, analyses of data from the Sequenced Treatment Alternatives to Relieve Depression clinical trial of sequences of treatments for depression and data from a clinical trial of respiratory treatments are presented. The estimation of individual benefits is also explained.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  chronic diseases; clinical trials; disease severity; empirical Bayesian prediction; generalized linear mixed-effects models; random effects linear models

Mesh:

Year:  2016        PMID: 27323698      PMCID: PMC5012921          DOI: 10.1002/sim.7005

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  19 in total

1.  Drug dosage individualization based on a random-effects linear model.

Authors:  Francisco J Diaz; Myladis R Cogollo; Edoardo Spina; Vincenza Santoro; Diego M Rendon; Jose de Leon
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

2.  Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.

Authors:  Francisco J Diaz; Michel J Berg; Ron Krebill; Timothy Welty; Barry E Gidal; Rita Alloway; Michael Privitera
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

3.  Can valproic acid be an inducer of clozapine metabolism?

Authors:  F J Diaz; C B Eap; N Ansermot; S Crettol; E Spina; J de Leon
Journal:  Pharmacopsychiatry       Date:  2014-04-24       Impact factor: 5.788

4.  The calculation of a confidence interval on the absolute estimated benefit for an individual patient.

Authors:  W Li; P Girard; J P Boissel; F Gueyffier
Journal:  Comput Biomed Res       Date:  1998-08

Review 5.  The relation between treatment benefit and underlying risk in meta-analysis.

Authors:  S J Sharp; S G Thompson; D G Altman
Journal:  BMJ       Date:  1996-09-21

6.  Modelling of individual pharmacokinetics for computer-aided drug dosage.

Authors:  L B Sheiner; B Rosenberg; K L Melmon
Journal:  Comput Biomed Res       Date:  1972-10

Review 7.  Meta-analysis in clinical research.

Authors:  K A L'Abbé; A S Detsky; K O'Rourke
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

Review 8.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

Review 9.  Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study.

Authors:  Maurizio Fava; A John Rush; Madhukar H Trivedi; Andrew A Nierenberg; Michael E Thase; Harold A Sackeim; Frederic M Quitkin; Steven Wisniewski; Philip W Lavori; Jerrold F Rosenbaum; David J Kupfer
Journal:  Psychiatr Clin North Am       Date:  2003-06

10.  Mastering variation: variance components and personalised medicine.

Authors:  Stephen Senn
Journal:  Stat Med       Date:  2015-09-28       Impact factor: 2.373

View more
  6 in total

1.  Construction of the Design Matrix for Generalized Linear Mixed-Effects Models in the Context of Clinical Trials of Treatment Sequences.

Authors:  Francisco J Diaz
Journal:  Rev Colomb Estad       Date:  2018-07

2.  Improvement in the long-term care burden after surgical treatment of patients with idiopathic normal pressure hydrocephalus: a supplementary study.

Authors:  Masatsune Ishikawa; Shigeki Yamada; Masakazu Miyajima; Hiroaki Kazui; Etsuro Mori
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

3.  The Supporting Patient Activation in Transition to Home (sPATH) intervention: a study protocol of a randomised controlled trial using motivational interviewing to decrease re-hospitalisation for patients with COPD or heart failure.

Authors:  Maria Flink; Marléne Lindblad; Oscar Frykholm; Åsa Kneck; Per Nilsen; Kristofer Årestedt; Mirjam Ekstedt
Journal:  BMJ Open       Date:  2017-07-10       Impact factor: 2.692

4.  A graphical approach to assess the goodness-of-fit of random-effects linear models when the goal is to measure individual benefits of medical treatments in severely ill patients.

Authors:  Zhiwen Wang; Francisco J Diaz
Journal:  BMC Med Res Methodol       Date:  2020-07-20       Impact factor: 4.615

5.  Measuring individual benefits of psychiatric treatment using longitudinal binary outcomes: Application to antipsychotic benefits in non-cannabis and cannabis users.

Authors:  Xuan Zhang; Jose de Leon; Benedicto Crespo-Facorro; Francisco J Diaz
Journal:  J Biopharm Stat       Date:  2020-06-08       Impact factor: 1.503

6.  Individualizing the dosage of Methylphenidate in children with attention deficit hyperactivity disorder.

Authors:  Hoda Shirafkan; Javad Mahmoudi-Gharaei; Akbar Fotouhi; Seyyed Ali Mozaffarpur; Mehdi Yaseri; Mostafa Hoseini
Journal:  BMC Med Res Methodol       Date:  2020-03-11       Impact factor: 4.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.